Biomarker and Diagnostics Strategy

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A group asked DeciBio to identify and evaluate clinical genetic testing labs for potential acquisition

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy